What is he best known for?
The fields of study he is best known for:
- Immune system
- Internal medicine
- Antibody
The scientist’s investigation covers issues in Immunology, Complement system, Cell biology, Antibody and Complement membrane attack complex.
Francesco Tedesco has researched Immunology in several fields, including Placenta and Glycoprotein.
His biological study spans a wide range of topics, including Hematology and Complement.
His Cell biology research incorporates elements of Cell adhesion, E-selectin and Classical complement pathway.
His research in Antibody tackles topics such as In vivo which are related to areas like Immunotherapy, CD20, Pharmacology and Monoclonal antibody.
His research in Rituximab intersects with topics in Cancer research and Antibody-dependent cell-mediated cytotoxicity, Cytotoxicity.
His most cited work include:
- Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis (551 citations)
- Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis (551 citations)
- Pathogenesis of antiphospholipid syndrome: understanding the antibodies (376 citations)
What are the main themes of his work throughout his whole career to date?
Francesco Tedesco mainly investigates Immunology, Complement system, Antibody, Cell biology and Molecular biology.
His work on Trophoblast expands to the thematically related Immunology.
The various areas that Francesco Tedesco examines in his Complement system study include Internal medicine, Biochemistry and Mannan-binding lectin.
His work deals with themes such as In vivo and Antigen, which intersect with Antibody.
His Antigen research focuses on subjects like Cytotoxicity, which are linked to Cancer research.
He works mostly in the field of Cell biology, limiting it down to topics relating to Endothelium and, in certain cases, Endothelial stem cell and Intravital microscopy.
He most often published in these fields:
- Immunology (44.91%)
- Complement system (34.72%)
- Antibody (21.76%)
What were the highlights of his more recent work (between 2012-2021)?
- Complement system (34.72%)
- Immunology (44.91%)
- Antibody (21.76%)
In recent papers he was focusing on the following fields of study:
Francesco Tedesco spends much of his time researching Complement system, Immunology, Antibody, Antiphospholipid syndrome and Internal medicine.
His Complement system research includes themes of Cancer research, Endothelium, Preeclampsia and Cell biology.
His research ties In vivo and Immunology together.
His studies deal with areas such as Antigen, Cytotoxicity, Leukemia, Chronic lymphocytic leukemia and Immunotherapy as well as Antibody.
The study incorporates disciplines such as Epitope, Autoantibody, Blood cell and Glycoprotein in addition to Antiphospholipid syndrome.
The Internal medicine study combines topics in areas such as Complement membrane attack complex, Endocrinology, Eculizumab and Cardiology.
Between 2012 and 2021, his most popular works were:
- Dynamics of complement activation in aHUS and how to monitor eculizumab therapy (195 citations)
- C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation (114 citations)
- A non–complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome (92 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Internal medicine
- Antibody
His main research concerns Complement system, Immunology, Antiphospholipid syndrome, Antibody and Thrombosis.
Francesco Tedesco interconnects Internal medicine and Virology in the investigation of issues within Complement system.
Francesco Tedesco is studying CD20, which is a component of Immunology.
His Antiphospholipid syndrome research integrates issues from In vitro, Inflammation, Glycoprotein, Phage display and In vivo.
His study in Antibody is interdisciplinary in nature, drawing from both Antigen, Cytotoxicity, Leukemia, Chronic lymphocytic leukemia and Immunotherapy.
He has included themes like Concomitant, Autoimmunity, Coagulopathy and C-reactive protein in his Thrombosis study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
